TY - JOUR
AU - Munblit, Daniel
AU - Bobkova, Polina
AU - Spiridonova, Ekaterina
AU - Shikhaleva, Anastasia
AU - Gamirova, Aysylu
AU - Nekliudov, Nikita A.
AU - Bugaeva, Polina
AU - Andreeva, Margarita
AU - DunnGalvin, Audrey
AU - Comberiati, Pasquale
AU - Apfelbacher, Christian
AU - Genuneit, Jon
AU - Kapustina, Valentina
AU - Guekht, Alla
AU - Fomin, Victor
AU - Svistunov, Andrey
AU - Timashev, Peter
AU - Subbot, Vladislav
AU - Royuk, Valery
AU - Drake, Thomas M.
AU - Hanson, Sarah Wulf
AU - Merson, Laura
AU - Carson, Gail
AU - Horby, Peter W.
AU - Sigfrid, Louise
AU - Scott, Janet T.
AU - Semple, Malcolm G.
AU - Warner, John
AU - Vos, Theo
AU - Olliaro, Piero L.
AU - Glybochko, Petr
AU - Butnaru, Denis
AU - Sechenov StopCOVID Research Team
PY - 2021
DA - August
TI - Incidence and risk factors for persistent symptoms in adults previously hospitalised for COVID-19
JO - Clinical and Experimental Allergy
EP - 1120
VL - 51
IS - 9
DO - http://dx.doi.org/10.1111/cea.13997
AB - Background: The long-term sequalae of COVID-19 remain poorly characterised. We assessed persistent symptoms in previously hospitalised patients with COVID-19 and assessed potential risk factors. Methods: Data were collected from patients discharged from 4 hospitals in Moscow, Russia between April 8 and July 10, 2020. Participants were interviewed via telephone using an ISARIC Long-term Follow-up Study questionnaire. Results: 2,649 of 4755 (56%) discharged patients were successfully evaluated, at median 218 (IQR 200, 236) days post-discharge. COVID-19 diagnosis was clinical in 1291 and molecular in 1358. Most cases were mild, but 902 (34%) required supplemental oxygen and 68 (2.6%) needed ventilatory support. Median age was 56 years (IQR 46, 66) and 1,353 (51.1%) were women. Persistent symptoms were reported by 1247 (47.1%) participants, with fatigue (21.2%), shortness of breath (14.5%) and forgetfulness (9.1%) the most common symptoms and chronic fatigue (25%) and respiratory (17.2%) the most common symptom categories. Female sex was associated with any persistent symptom category OR 1.83 (95% CI 1.55 to 2.17) with association being strongest for dermatological (3.26, 2.36 to 4.57) symptoms. Asthma and chronic pulmonary disease were not associated with persistent symptoms overall, but asthma was associated with neurological (1.95, 1.25 to 2.98) and mood and behavioural changes (2.02, 1.24 to 3.18), and chronic pulmonary disease was associated with chronic fatigue (1.68, 1.21 to 2.32). Conclusions: Almost half of adults admitted to hospital due to COVID-19 reported persistent symptoms 6 to 8 months after discharge. Fatigue and respiratory symptoms were most common, and female sex was associated with persistent symptoms.
PB - Wiley
UR - http://eprints.gla.ac.uk/248899/
KW - Coronavirus (COVID-19)
ER